Crucell and NIH sign EUR 21.4 million Ebola Vaccine Manufacturing Contract
Crucell N.V. announced that it has signed a manufacturing contract with the Vaccine Research Center (VRC), part of the National Institute of Allergy and infectious diseases (NIAID) of the National Institutes of Health (NIH), for the manufacture of vaccines against Ebola infections.
Under the terms of the contract, Crucell will manufacture up to ten batches of clinical material of the PER.C6®-based Ebola vaccine in its own manufacturing facility. These materials will be used for Phase I and early Phase II clinical studies in humans. Crucell will receive up to EUR 21.4 million (US$ 27.6 million) from the VRC for the manufacturing of these clinical lots.
Most read news
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Category:Enteral_feeding

Oxygen deficiency rewires mitochondria - Researchers slow the growth of pancreatic tumour cells
Category:Biology
Category:Anatomical_preservation
Munchausen_syndrome
Zinc_oxide_eugenol
Migraine may permanently change brain structure

Hydrogen-producing living droplets paving way for alternative future energy source - A step towards photobiological green energy development under natural aerobic conditions
Haplogroup_F_(Y-DNA)
